Clinical Trials
Don't miss this issue of The Altascientist
Shortening Drug Development Timelines with Asian Ethnobridging Trials
Developing drugs for the Asian market may require that Phase I studies be repeated in regions outside North America and Europe. Altasciences has the clinical capabilities to demonstrate biosimilarity of drug products between Asian and non-Asian populations by comparing pharmacokinetics of the investigational drug in both ethnic groups, providing a safe strategy to save time and money.
In our latest issue of The Altascientist, using case studies, we discuss how ethnobridging can prevent the necessity of regional-specific development programs, helping you achieve commercial milestones safely and more efficiently.
Download your copy today! Listen to the audio recording!
Speak with an expert today to discuss your next study!
Got a few more minutes? You may also be interested in the following webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
[NEW PODCAST] Microsampling: When Small Steps Lead to Big Outcomes
Microsampling: When Small Steps Lead to Big Outcomes
Join us as Dr. Donald Chace and Jeff Plomley discuss the many advantages of incorporating microsampling into your drug development program.
Altasciences is at the forefront of microsampling, leveraging innovative technology that allows for significantly reduced blood volumes to be taken from test subjects for analysis. Our experts have developed specialized workflows and methods to take full advantage of current microsampling technology at the preclinical, clinical, and bioanalytical levels, supporting the efficient advancement of your drug development program. Our services are fully customizable, available as stand-alone, or as part of a complete development program.
You may also be interested in the following:
- The Altascientist: Microsampling in Drug Development
- Webpage: Patient Centricity and the Evolving Role of Microsampling
- Webpage: Comprehensive Bioanalytical Services
- PDF: Altasciences' Proprietary Bioanalytical Assay List
Transforming the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, Altasciences offers a unique integrated approach to CRO and CDMO s
Case Study― Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of Palovarotene (POS)
Reduce Your Drug Development Costs and Delays
Benefit from Partnering with a Single CRO/CDMO Partner―From Formulation to Preclinical to Clinical
The drug development journey often involves working with different CRO and CDMO partners. But there’s a simpler, more efficient solution!
Altasciences’ fully integrated, end-to-end offering means seamless transition from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This reduces complex handoffs, communication errors, and delays.
Discover how we support you through each phase of your drug development.
Related pages:
- Webpage: Formulation, Development, and Manufacturing Solutions
- Virtual Tour: Manufacturing Facility and Analytical Laboratories
- Webinar: Overcoming Challenges of Manufacturing in Clinical Trials
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Flow Lab—Minutes Away From our Clinical Unit
Benefits of Partnering with Altasciences for Your Flow Cytometry Services
Our bioanalytical laboratory is located 15 minutes from our Montréal clinical pharmacology unit, creating an efficient process that allows rapid turnaround time between sample collection and analysis.
The close proximity between the clinic and our lab:
- prevents potential risks at the primary endpoints of these types of trials
- certifies rapid results analysis and reporting
- ensures safe and seamless dose escalations for FIH trials
- proven to lower costs
To safely expedite the bioanalytical phase of your preclinical or clinical study or program, our flow cytometry services will help you get there.
Book a consult with one of our experts today, to discuss how we can support your single study or program.
You may also be interested in the following:
- Webpage:
- Podcast:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programmes, to offer an integrated/synchronized approach to CRO and CDMO services.
Accelerate the Development of Your CNS-Active Drugs with Pharmacodynamic Measures
Accelerate the Development of Your CNS-Active Drugs with Pharmacodynamic Measures
Strategic design and targeted use of pharmacodynamic measures can greatly assist in evaluating the safety and potential efficacy of your new drug candidate in the early stages of clinical development.
In this on-demand webinar, our experts discuss how to include validated models of pain, anxiety, and other psychiatric conditions as part of a battery of tests for cognition and safety, to evaluate a drug’s potential for abuse or dependence, as well as its ability to enhance or impair performance.
You may also be interested in the following:
- The Altascientist: Considerations for Your CNS-active Drug Development Program
- Webinar — Assessing Cognition and Driving Ability in Clinical Pharmacology Studies
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programmes, to offer an integrated/synchronized approach to CRO and CDMO services.
Formulation to Clinic―Navigating the Complexities of Ophthalmic Drug Development
Helping You Navigate the Complexities of Ophthalmic Drug Development
Ophthalmic drug development comes with a unique set of challenges and complexities. To maximize your chance of success, it is best to rely on a drug development partner with regulatory knowledge, scientific and technical expertise, and a thorough understanding of the market in this growing therapeutic area.
Altasciences’ clients benefit from working with a single CRO/CDMO partner, from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in both time and cost savings.
Learn about the key considerations and critical steps in each phase of ophthalmic drug development, including case studies, in this issue of The Altascientist.
Have questions? Speak with one of our experts.
You might also be interested in:
- Webpage: Full-Service Drug Development Solutions
- Scientific Article: Terminal Sterilization of Pharmaceutical Products
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Five Reasons to Place Early Phase Clinical Research in Canada
A well-planned clinical program designed to meet the regulatory requirements for the jurisdictions where you plan to request market authorization can be conduct
Access Earlier Clinical Data to Accelerate Your Program
Phase I and II Combined Protocols Can Give You Earlier Access to Important Data—Here’s How
Have you considered combining Phase I and II protocols to advance certain analyses? Think DDI, QT assessment, food, age, or gender affect, or cognitive or dependence evaluation. With earlier access to this highly relevant data, you have the power to make more informed decisions as you progress your drug through development, and possibly obtain a waiver for certain later-phase studies.
Our experts in protocol development are ready to design your ideal program, giving you the earliest, most complete understanding of your developmental product.
Read The Altascientist for a more complete discussion on combined protocols, including two scenarios.
DOWNLOAD your copy, or listen to the AUDIOBOOK.
Have five more minutes? Browse these webpages for more important information:
- First-in-Human Clinical Trials
- Early Phase Drug Development Solutions
- Clinical Development Solutions
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO service